Mary Christina Thomson
Network origin in Mary Christina Thomson first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Extinct | Biotechnology | 28 | |
Avigen, Inc.
 Avigen, Inc. Medical SpecialtiesHealth Technology Avigen, Inc. produces and sells drugs, animal health products, and chemicals. The firm also develops and commercializes small molecules of therapeutics and biologics for use in the treatment of serious neurological and neuromuscular disorders. The company was founded in 1992 and is headquartered in La Jolla, CA.
14
| Subsidiary | Medical Specialties | 14 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Mary Christina Thomson via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal | |
MedImmune Vaccines, Inc.
 MedImmune Vaccines, Inc. BiotechnologyHealth Technology MedImmune Vaccines, Inc. develops, manufactures and markets live vaccines. Its developed vaccine is inhaled FluMist. The company is located in Mountain View, CA | Biotechnology | General Counsel | |
| AVAX TECHNOLOGIES, INC. | Biotechnology | Chief Executive Officer | |
| DYNAVAX TECHNOLOGIES CORPORATION | Biotechnology | General Counsel | |
Viventia Biotech, Inc.
 Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | Biotechnology | Chief Tech/Sci/R&D Officer Chief Operating Officer | |
JPMorgan Securities LLC
 JPMorgan Securities LLC Investment Banks/BrokersFinance JPMorgan Securities LLC (JPMS) is a securities brokerage firm headquartered in New York City. The firm was founded in 1985 and is a subsidiary of JPMorgan Broker-Dealer Holdings, Inc., ultimately held by JPMorgan Chase & Co., Inc. (NYSE: JPM). JPMS provides research on fixed income, credit, derivatives, emerging markets, foreign exchange, structured finance, technical analysis and bond indices. Their equity analysts cover equities throughout North America, EMEA, Asia/Pacific and the emerging markets. The firm's fixed income team formulates trading and portfolio recommendations for investors in global bonds and other fixed-income markets based on valuations, analytics and market dynamics. | Investment Banks/Brokers | Private Equity Analyst | |
Elusys Therapeutics, Inc.
 Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Piramed Ltd.
 Piramed Ltd. Miscellaneous Commercial ServicesCommercial Services PIramed Ltd. develops drugs, diagnostics, and other therapeutic products. It develops treatment for cancers which include proliferation, invasion, angiogenesis, and metastasis. The company was co-founded by Michael Waterfield, Peter Parker, and Paul Workman in 2003 and is headquartered in Slough, UK. | Miscellaneous Commercial Services | Director/Board Member | |
General Nutrition Centers, Inc.
 General Nutrition Centers, Inc. Food RetailRetail Trade General Nutrition Centers, Inc. engages in the retail of nutritional supplementary products. It provides vitamin, mineral, herbal and other specialty supplements and sports nutrition, diet and energy products. The company was founded in October 2003 and is headquartered in Pittsburgh, PA. | Food Retail | Director/Board Member | |
| CODEXIS, INC. | Chemicals: Specialty | Chief Executive Officer Chief Operating Officer Public Communications Contact | |
| MEDICINOVA, INC. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer Director of Finance/CFO Director/Board Member | |
| SOLENO THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| ARBUTUS BIOPHARMA CORPORATION | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Human Resources Officer | |
| HSBC Global Markets Select Funds Plc | Investment Trusts/Mutual Funds | Director/Board Member | |
Abingworth Management Ltd.
 Abingworth Management Ltd. Investment ManagersFinance Abingworth Management Ltd. operates as an investment firm with interests in the life sciences and healthcare sectors. It offers services for businesses in all stages of company development, including early and late-stage venture financing, growth equity, and public companies. The company was founded in 1973 and is headquartered in London, the United Kingdom. | Investment Managers | Corporate Officer/Principal | |
| SCORPIUS HOLDINGS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Abingworth Bioventures VI LP
 Abingworth Bioventures VI LP Investment ManagersFinance Abingworth Bioventures VI LP invests in private and public companies located the US and Europe. The fund targets companies operating in the fields of medical devices, instrumentation, bio therapeutics, small molecules, nucleic acid therapeutics, vaccines, specialty pharma, technologies, diagnostics and software. The fund provides financing for seed, early and late stage capital requirements with an investment size of $15 - $30 million. It seeks Majority or minority investments in the companies. | Investment Managers | Director/Board Member | |
| University of Pittsburgh | College/University | Doctorate Degree | |
| University of Pennsylvania | College/University | Masters Business Admin Corporate Officer/Principal | |
Needham & Co. LLC
 Needham & Co. LLC Investment Banks/BrokersFinance Needham & Co. LLC (Needham) is a registered investment advisor and broker/dealer headquartered in New York City. The firm was founded in 1985 and is a wholly-owned indirect subsidiary of The Needham Group, Inc. Needham provides corporate and institutional clients with high quality research, corporate access, capital markets and trading execution services in both the public and private markets, with an emphasis on growth companies. | Investment Banks/Brokers | Analyst-Equity | |
Abingworth LLP
 Abingworth LLP Investment ManagersFinance Abingworth LLP (Abingworth) is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. Abingworth LLP became part of The Carlyle Group Inc. (NASDAQ: CG) on 3rd August 2022. | Investment Managers | Private Equity Analyst | |
Institute of Chartered Accountants in England & Wales
 Institute of Chartered Accountants in England & Wales Miscellaneous Commercial ServicesCommercial Services The Institute of Chartered Accountants in England & Wales ensures that its members, students, and affiliates maintain the highest standards of professional competency and conduct to protect the public interest. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. With over 150,000 members, the institute provides technical information, helplines, and communities to its members. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| University of California, Los Angeles | College/University | Undergraduate Degree Doctorate Degree Graduate Degree | |
| Queen's University | College/University | Masters Business Admin Graduate Degree Undergraduate Degree | |
Credit Suisse Securities (Europe) Ltd.
 Credit Suisse Securities (Europe) Ltd. Investment Banks/BrokersFinance Credit Suisse Securities (Europe) Ltd. (Credit Suisse Europe) is the Great Britain-based brokerage subsidiary of Credit Suisse Investment Holdings (UK), itself a subsidiary of Credit Suisse Group AG (SWX: CSGN) in Switzerland. The firm was founded in 1966 and formerly known as Credit Suisse First Boston (Europe) Ltd. Headquartered in London, Credit Suisse Europe arranges financing in international capital markets, provides financial advisory services and acts as a dealer in securities, derivatives and foreign exchange on a principal and agency basis for corporate and institutional investors. | Investment Banks/Brokers | Analyst-Equity | |
| The California State University | College/University | Undergraduate Degree | |
| University of Alberta | College/University | Graduate Degree Doctorate Degree | |
| University of California, Berkeley | College/University | Undergraduate Degree | |
| University of California, Davis | College/University | Undergraduate Degree Doctorate Degree Undergraduate Degree Undergraduate Degree | |
| University of California, Santa Barbara | College/University | Corporate Officer/Principal Undergraduate Degree | |
| LaTrobe University | College/University | Masters Business Admin Masters Business Admin | |
HSBC Bank Plc (Broker)
 HSBC Bank Plc (Broker) Investment Banks/BrokersFinance HSBC Bank Plc (Broker) (HSBC Bank-Broker) is the broker/dealer division of HSBC Bank Plc, which is owned by HSBC Holdings Plc (LON: HSBA; NYSE: HSBC) in Great Britain. Headquartered in London, HSBC Bank-Broker was founded in 1880 and offers bespoke brokerage services across every major asset class for their corporate and institutional clients. | Investment Banks/Brokers | Analyst-Equity | |
| VERONA PHARMA PLC | Pharmaceuticals: Major | Director/Board Member | |
OrbiMed Advisors Private Equity
 OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Investment Managers | Private Equity Investor | |
| King's College London | College/University | Undergraduate Degree | |
| AIMMUNE THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal Sales & Marketing | |
| SPARK THERAPEUTICS, INC. | Biotechnology | Founder Founder | |
Neurana Pharmaceuticals, Inc.
 Neurana Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Neurana Pharmaceuticals, Inc. engages in a biotechnology industry. It focused on the development of drugs to treat neuromuscular disorders. The company was founded in 2013 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Disc Medicine Opco, Inc.
 Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
| DISC MEDICINE, INC. | Biotechnology | Director/Board Member | |
| PREVAIL THERAPEUTICS INC. | Biotechnology | Director/Board Member | |
| VERA THERAPEUTICS, INC. | Biotechnology | Corporate Officer/Principal | |
| ADICET BIO, INC. | Pharmaceuticals: Major | Director/Board Member | |
Locki Therapeutics Ltd.
 Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases. | Biotechnology | Director/Board Member |
Statistics
International
| United States | 33 |
| United Kingdom | 12 |
| Canada | 5 |
| Ireland | 2 |
| Australia | 2 |
Sectoral
| Health Technology | 27 |
| Consumer Services | 12 |
| Finance | 9 |
| Commercial Services | 3 |
| Retail Trade | 2 |
Operational
| Director/Board Member | 122 |
| Corporate Officer/Principal | 76 |
| Independent Dir/Board Member | 48 |
| Chief Tech/Sci/R&D Officer | 30 |
| Undergraduate Degree | 28 |
Most connected contacts
| Insiders | |
|---|---|
| Gaurav Aggarwal | 21 |
| Andrew Allen | 18 |
| Georgia Erbez | 18 |
| Craig Collard | 18 |
| John Monahan | 17 |
| Glenn F. Pierce | 17 |
| John Prendergast | 16 |
| Stephen Dilly | 15 |
| Andrew Sinclair | 14 |
| Jan Öhrström | 13 |
| Robert E. Pelzer | 12 |
| Barbara Klencke | 12 |
| Michael Denis Coffee | 11 |
| Jeffrey Cooper | 11 |
| Richard Wallace | 11 |
- Stock Market
- Insiders
- Mary Christina Thomson
- Company connections
